Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.
Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen: Berner Fachhochschule; We are currently in negotiations with two university hospitals (University Hospital Erlangen, Germany and Insel Hospital Berne, Switzerland) in order to initiate the required clinical studies to demonstrate that our product is able to increase treatment quality and to reduce the treatment costs.
Förderbeitrag: CHF 150'000
Dauer: 09.2018 - 06.2020
Handlungsfeld: First Ventures, seit 2018
4600 Olten (Schweiz)
- kevin.tippenhauer@bfh. ch
The aim of our project is a release candidate of a pharmacogenetic clinical decision support service (PGCDSS). Pharmacogenetics is the study of genetic effects on the metabolic pathways of drugs. 95% of individuals carry one or more genetic variants that are important for drug dosing recommendations. There are currently 225 drugs with known pharmacogenetic interactions. Ignoring genetic variations while prescribing a drug can cause severe adverse drug reactions (ADR), e.g. death or completely insufficient drug response such as lacking pain relief for an analgesic. Our service has the potential to reduce inadequate drug prescriptions for patients with certain genetic constellations considerably.
The treatment of severe ADRs is expensive, and it has been demonstrated that the costs for additional treatment of patients suffering ADRs can be higher compared to genome analysis of all patients receiving the drug. Despite these benefits of pharmacogenetics, the actual implementation in clinical routine is progressing slowly, not because genetic knowledge is missing, but because of problems concerning the transfer of this knowledge to the point-of-care. A PGCDSS service reduces the hurdles and costs of for different health care providers to use pharmacogenetic knowledge.
The projected PGCDSS service analyses the individual pharmacogenetic data and warns the physician in case of critical drug prescriptions. Thus the service has the potential to reduce severe pharmacogenetic ADRs. The system can provide alerts and patient-specific drug recommendations. The PGCDSS can be part of a clinical information system, but it can also be provided by an external service. In both cases, the PGCDSS shall be seamlessly integrated into the physicians’ workflow.
Was ist das Besondere an diesem Projekt?
Pharmacogenetics is relevant for almost every physician prescribing drugs; the bandwidth of pharmacogenetically relevant drugs ranges from highly specialised anti-cancer medications to very common drugs like codeine. We will provide a PGCDSS that can easily be integrated with the different IT systems of the healthcare providers. Furthermore, our suggested solution can be seamlessly integrated into the physicians’ prescription workflow and thus has low adaptation costs. We expect that decision support systems will become mandatory in the drug prescription process in future, opening new markets for services such as the one described here.
In our thesis, we developed a first prototype of a pharmacogenetic clinical decision support system and implemented it in the test system of the University Hospital in Berne, Switzerland.
None so far
Am Projekt beteiligte Personen
Letzte Aktualisierung dieser Projektdarstellung 12.06.2019